Skadden is advising BridgeBio Pharma, Inc. in its approximately $1 billion acquisition of the remaining 36% stake in Eidos Therapeutics, Inc. that it does not already own.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is advising BridgeBio Pharma, Inc. in its approximately $1 billion acquisition of the remaining 36% stake in Eidos Therapeutics, Inc. that it does not already own.